⚠️ Uptrend Under Pressure Severe risk · 99 · Institutional selling is building — 6 distribution days in the last 25 sessions. · 6 distribution days (SPY) Full briefing → Jul 28
Simple research view

ABBV · AbbVie Inc.

$256.91 latest stored close
Detected setup VCP

Watch · Quality 22/100

Ask about ABBV

Switch to Advanced for indicator panels, raw grades, provenance, drawing tools, and full technical tables.

Scans / Health Technology / ABBV

$ABBV

AbbVie Inc.

AbbVie Inc. is a mega-cap Pharmaceuticals: Major company in the Health Technology sector with a market cap of $454B.

Strong Buy · 90 Health Technology Pharmaceuticals: Major stock Stage 2 · Advancing Base 2 Data 53m ago
$256.91 latest close
← Back Join to Watchlist $ABBV Share card
Council read · 6 methods

Watch — evidence is building

0 buyable · 4 watch · 2 avoid. Review the observed passes and blockers before reading the chart.

Review six verdicts Inspect chart
Earnings-risk mode

Pre-earnings setup

Thursday, July 30, 2026 Time not confirmed No sourced report session or clock time

Deterministic evidence

ABBV-0.94%
Sector proxy · XLV+0.51%
Broad market · SPY+0.02%
Same completed session window ending 2026-07-27. ABBV was -1.45 points vs XLV. -0.96 points vs SPY.
CatalystUnavailable Stock reactionNegative Sector reactionSupportive Opening surgeUnavailable Event riskEarnings-driven
Price bars, sourced event fields, and benchmark math only. This can adjust displayed short-term conviction; it does not change the stored scanner score or readiness.

AI interpretation (optional)

Ask a Legend to interpret the evidence only after reviewing the deterministic event timing and relative reaction.

Interpret this evidence AI output is commentary, not scanner evidence or a sizing recommendation.
Price $256.91 Jul 27 close
52W High $262.10 -2.0%
52W Low $187.62
Wks Since High 0w
Base B2
SMA 50 $234.26
SMA 200 $224.13
Avg Vol 6,970,666
RS Rank 74
RS vs High -4.9%
RS Slope +1.3% ▲
Grp Rank #16/64
ADR% 2.3%
ATR(14) $5.61 (2.2%)
Rel Vol (today) 0.78×
Vol Pace N/A
U/D Vol 0.79
A/D Days 12A / 9D
A/D Rating A
VDU Bars 0/10 d
Power Trend 25d
Earnings 2d
$187.62
$262.10 93%

ABBV Chart

Interactive price, volume, RS, RSI, and MACD charts are available after sign in.

Create a free account to load the full interactive chart for ABBV.

Create Free Account
Setup Quality B+ 5/7 signals
Jul 24: 89 (VCP)Jul 27: 90 (VCP)Jul 27: 91 (VCP)Jul 28: 89 (VCP)Jul 28: 90 (VCP)90 Score trend
✓ Stage 2 · Advancing ✓ Power Trend 25d ✗ RS New High ✓ Trend 7/8 ✗ No Pattern ✓ CANSLIM 74.4 (B) ✓ Gatekeeper Base #2 (B)

See the full conviction stack.

Unlock Insights

Technical Analysis Report Card

$ABBV · $256.91 · as of 2026-07-27 · multi-factor read
90
/ 100
Strong Buy

Trend · Daily / Weekly / Monthly

Daily ▲ Uptrend
Weekly ▲ Uptrend
Monthly ▲ Uptrend

Moving Averages

50-day$234.26 ↑
100-day$222.48 ↑
200-day$224.13 ↑
Golden Cross (fresh)

RSI (14)

Reading62.3 · Bullish

Bullish momentum — comfortably in buyer territory.

MACD (12/26/9)

StateWeakening
Histogram-0.460

Weakening — MACD slipped below its signal line. Histogram contracting.

Bollinger Bands (20,2)

%B / Width72% · 7.0%
Squeeze — volatility compressing

Mid-band — no directional band edge in play. Bands are squeezing — volatility is compressing, often a precursor to a sharp move.

Volume · Buyer vs Seller

Up/Down vol0.79 · Neutral
Rel volume0.78×

Balanced — up/down volume is roughly even; no clear hand. Recent volume is easing versus its baseline.

Support & Resistance

R · $261.3052-week high
Price · $256.91now
S · $243.07swing level
S · $221.12swing level
S · $216.62swing level

Fibonacci · Uptrend swing

23.6%$245.26
38.2%$234.84
50.0%$226.43
61.8%$218.01
78.6%$206.02

Retracement support zones measured from the recent swing low up to the high.

The verdict is free. The trade plan is Pro.
Unlock the exact entry, stop-loss, profit target, and reward-to-risk for ABBV — plus the full 495-symbol scanner and Ask-the-Legends chat.
🔒 Start your 7-day free trial →
Daily uptrendWeekly uptrendMonthly uptrendAbove 200-day MA50/200 bullish
Want this read in a legend's voice? 💬 Ask a Legend about ABBV
Generic technical analysis generated mechanically from price & volume — educational research only, not financial advice or a personalized recommendation. Levels are illustrative; confirm on your own chart. New to these terms? →
Legend Verdicts 6 methodology checks

Who would consider this setup, why it qualifies, and what blocks it — calculated from the same deterministic methodology rules used across Legend AI.

Council consensus: 🟡 4 of 6 legends are Watching — building, not yet a confirmed buy.
Minervini
Avoid
Minervini B

Trend-template read: fails 150-day MA > 200-day MA.

Passing evidence
1.1 Price > 150-day MA AND 200-day MAPrice $256.91, MA150 $223.20, MA200 $224.13
1.4 50-day MA > 150-day MA AND 200-day MAMA50 $234.26, MA150 $223.20, MA200 $224.13
Failing evidence
1.2 150-day MA > 200-day MAMA150 $223.20 vs MA200 $224.13
2. Quarterly EPS growth ≥ 25%-2.2% QoQ
9/12 checks
Method → Playbook → Ask →
O'Neil
Avoid
O'Neil D

CANSLIM read: fails C: Quarterly EPS acceleration ≥ 25%.

Passing evidence
A: Annual earnings & revenue qualityRev +8.6% | ROE 95.6%
N: Near 52-week high or RS line new high2.0% below high | RS line new high: False
Failing evidence
C: Quarterly EPS acceleration ≥ 25%-2.2% QoQ
L: RS rank ≥ 80 (IBD leadership)RS rank 72
3/8 checks
Method → Playbook → Ask →
Weinstein
Watch
Weinstein C

Stage-analysis read: Stage 2 is present; 2 supporting checks need improvement.

Passing evidence
Stage 2 (Advancing phase) confirmedStage 2 (Advancing)
Price above 30-week MA (200-day proxy)Price $256.91 vs MA200 $224.13
Failing evidence
Volume expansion above averageVolume ratio 0.78x
Weekly price coiling (Stage 2 consolidation)Tightening weekly range confirms base
5/7 checks
Method → Playbook → Ask →
Livermore
Watch
Livermore B

Pivotal-point read: constructive evidence is present, but volume vs average is unresolved.

Passing evidence
Price$256.91
Relative strengthRS 72
Failing evidence
Volume vs average0.78x
Pivotal point cleared on expanding volumeNot confirmed
4/6 checks
Method → Playbook → Ask →
Darvas
Watch
Darvas B

Box-theory read: constructive evidence is present, but volume vs average is unresolved.

Passing evidence
Price$256.91
Relative strengthRS 72
Failing evidence
Volume vs average0.78x
Box top broken on heavy volumeNot confirmed
4/6 checks
Method → Playbook → Ask →
Wyckoff
Watch
Wyckoff B

Supply-and-demand read: constructive evidence is present, but volume vs average is unresolved.

Passing evidence
Price$256.91
Relative strengthRS 72
Failing evidence
Volume vs average0.78x
Sign of Strength confirmed on expanding volumePrice hasn't cleared the pivot yet — confirmation pending
4/6 checks
Method → Playbook → Ask →
Breakout Health

No active breakout tracked — Legend AI monitors daily for pivot-point breaks. What's a breakout?

🕯 Latest candle: Bearish Engulfing — Today's down candle engulfs yesterday's up candle — a bearish reversal warning, most significant after an extended advance.

Unlock Follow-Through Tracking
RS Line vs SPY 52-week relative strength · blue = RS line · dashed = MA50 · dot = NH ▲ Rising
117RS Line (52W)
Accumulation / Distribution last 65 sessions · green = acc on high vol · red = dist on high vol Net +3 A
A: 15 D: 12 Net: +365 sessions
Minervini · Grade Card
Fundamentals & leadership quality — Minervini SEPA criteria · 4/7 met
B 4/7 SEPA
Separate score from the 8-point Trend Template (7/8): the Trend Template grades the price structure, this grades the company & leadership (earnings, sales, margins, RS rank). A stock can ride a clean trend while its fundamentals lag, so the two often differ by design — they are not the same checklist.
✗ EPS acceleration ≥25% QoQ -2%
✗ Revenue growth ≥20% YoY +9%
✓ Gross margin ≥30% 72%
✓ ROE ≥17% 96%
✗ RS rating ≥80 (leadership) 72
✓ Stage 2 uptrend (Weinstein) Stage 2
✓ Within 25% of 52W high -2.0%

Method Playbook

📋 Trade it like O'Neil EXACT LEVELS · PRO
Minervini O'Neil Livermore Weinstein Darvas Wyckoff
O'Neil D · Avoid — The deterministic methodology check is Avoid; wait until the blocking criteria are resolved.
Pivot
Pro level
Published-method rule: Use the proper base pivot or handle high after CANSLIM leadership and market-direction checks are satisfied.
Evidence: Canonical setup geometry is available with Pro.
Entry trigger
Pro level
Published-method rule: Require a breakout through the pivot on volume at least 40% above average; the valid buy zone ends 5% above the pivot.
Evidence: Canonical setup geometry is available with Pro.
Initial stop
Pro level
Published-method rule: Use the setup's structural stop with a hard 7–8% maximum-loss ceiling from the actual entry.
Evidence: Canonical setup geometry is available with Pro.
Trail
Rule-based
Published-method rule: Protect progress under constructive support such as the 21-day or 10-week line; a stop may ratchet higher but never lower.
Evidence: Planned management rule; no stored stop or broker order is changed automatically.
Exit / invalidation
Pro level
Published-method rule: Exit on the hard loss limit, a decisive support break, or a rule-based climax/distribution signal; a normal 20–25% advance is reviewed rather than assumed permanent.
Evidence: Canonical setup geometry is available with Pro.
Deterministic educational plan, not a recommendation. No order or stop is changed automatically. Method and sources →
The published-method workflow is public. Unlock exact pivot, entry, stop, target, and sizing with Pro →

Pattern Analysis

VCP
89.5 score
RS Score 72
Trend 7/8 ✓
CANSLIM 74.4* (B)
C1 7.1%
→
C2 3.3%
2 contractions 7.1% depth ✓ tightening ✓ vol dry ✓ near pivot ✓ right side Q: 88
Why This Setup?
VCP

2T: 7% → 3% (tightening, higher lows), depth=7.1%, vdu=0.69, state=actionable, quality=88 | Strong trend (7/8) | Good RS (72) | High-confidence pattern (100%) | Power Trend | Stage 2 | Readiness 79/100 (watch) | CANSLIM 74.4 (B)

Ask a Legend ▾
The Universal Edge Check

The panel is uneasy

Too many universals unmet — this leans closer to a guess than a trade.

1/7 universals met
Why these seven? → The Universal Edge

Minervini Trend Template

7/8

Grades the price structure — moving-average stacking, distance from the 52-week high/low, and relative strength above the ≥70 uptrend bar. This is the technical trend check; the company's fundamentals and ≥80 RS leadership are scored separately in the Grade Card.

Price above SMA 150 & 200 $256.91 vs SMA150 $223.20 / SMA200 $224.13
SMA 150 above SMA 200 SMA150 $223.20 vs SMA200 $224.13
SMA 200 trending up Slope +2.87 over 20 days
SMA 50 above SMA 150 & 200 SMA50 $234.26
Price above SMA 50 $256.91 vs SMA50 $234.26
30%+ above 52W low +36.9% from $187.62
Within 25% of 52W high -2.0% from $262.10
RS score above 70 RS 72

Fundamentals

52W Range
93%
Mkt Cap SEC
453.9B
EPS QoQ
-2%
Rev YoY
+9%
ROE
96%
Gross Margin
72%
D/E
20.19
EPS TTM
$2.36
P/E TTM
108.9x
Float
1.8B
Insider
No Buy

Company

Legend AI snapshot
AbbVie Inc.
ABBV · NYSE · Health Technology · Pharmaceuticals: Major
$256.91latest close $453.9Bmarket cap 74RS rank 90setup score
Track all markets on TradingView
O'Neil · Grade Card
CANSLIM — current EPS, annual EPS, new highs, supply, leader RS, inst. sponsorship, market
B 74.4* CANSLIM * disqualified on C, M
C · Curr. EPS
52
A · Annual EPS
100
N · New Highs
100
S · Supply/Demand
55
L · Leader RS
72
I · Inst. Spons.
96
M · Market
30

Weekly Context

Multi-timeframe signals from weekly bars
W. Trend
7/8
W. RS
82
W. Support
$190.75
W. Resist
$261.64
Weekly Structure

Scan History

20× streak
Jul 24: 89 (VCP)Jul 27: 90 (VCP)Jul 27: 91 (VCP)Jul 28: 89 (VCP)Jul 28: 90 (VCP)90
Jul 28
VCP ✓ Gate
90
Jul 28
VCP ✓ Gate
89
Jul 27
VCP ✓ Gate
91 0.0%
Jul 27
VCP ✓ Gate
90 0.0%
Jul 24
VCP ✓ Gate
89 -0.9%

Get the full picture on ABBV

Pro members see entry/stop/target levels, R:R ratios, intraday alerts, and every setup detected across 495+ symbols daily.

Start 7-Day Free Trial